Selamectin is the avermectin with the best potential for Buruli ulcer treatment

PLoS Neglected Tropical Diseases

Volumn 9, Issue 8, 2015, Pages

  Scherr, Nicole ^a,b   Pluschke, Gerd ^a,b   Thompson, Charles J ^c   Ramón García, Santiago ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABAMECTIN; AVERMECTIN; DORAMECTIN; EMAMECTIN; EPRINOMECTIN; IVERMECTIN; MACROLIDE; MILBEMYCIN; MOXIDECTIN; SELAMECTIN; UNCLASSIFIED DRUG; ANTIPARASITIC AGENT;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BURULI ULCER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG POTENCY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM MARINUM; MYCOBACTERIUM ULCERANS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIPARASITIC AGENTS; BURULI ULCER; HUMANS; IVERMECTIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM ULCERANS;

EID: 84940659470     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003996     Document Type: Article

References (31)

1. Ellen D.E. et al. Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli ulcer functional limitation score. Tropical medicine & international health: TM & IH 8, 90-96 (2003).
2. http://www.who.int/buruli/en/
3. Nienhuis W.A. et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375, 664-672 (2010).
4. Marsollier L. et al. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother 47, 1228-1232 (2003).
5. DiMasi J.A., Hansen R.W. & Grabowski H.G. The price of innovation: new estimates of drug development costs. J Health Econ 22, 151-185 (2003).
6. Payne D.J., Gwynn M.N., Holmes D.J. & Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6, 29-40 (2007).
7. Ramon-Garcia S. et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high throughput screen. Antimicrob Agents Chemother (2011).
8. Chong C.R. & Sullivan D.J. Jr. New uses for old drugs. Nature 448, 645-646 (2007).
9. Lim L.E. et al. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother 57, 1040-1046 (2013).
10. Omansen T.F. et al. In-vitro activity of avermectins against Mycobacterium ulcerans. PLoS neglected tropical diseases 9, e0003549 (2015).
11. Montoro E. et al. Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 55, 500-505 (2005).
12. Prichard R., Menez C. & Lespine A. Moxidectin and the avermectins: Consanguinity but not identity. International journal for parasitology. Drugs and drug resistance 2, 134-153 (2012).
13. Thuan N.H., Pandey R.P. & Sohng J.K. Recent advances in biochemistry and biotechnological synthesis of avermectins and their derivatives. Applied microbiology and biotechnology 98, 7747-7759 (2014).
14. Omura S. & Crump A. The life and times of ivermectin-a success story. Nature reviews. Microbiology 2, 984-989 (2004).
15. https://clinicaltrials.gov/ct2/show/NCT00790998
16. Ramon-Garcia S. et al. Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent. J Antimicrob Chemother 69, 1723-1724 (2014).
17. Guzzo C.A. et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. Journal of clinical pharmacology 42, 1122-1133 (2002).
18. Gonzalez Canga A. et al. The pharmacokinetics and interactions of ivermectin in humans-a minireview. The AAPS journal 10, 42-46 (2008).
19. Daurio C.P., Cheung E.N., Jeffcoat A.R. & Skelly B.J. Bioavailability of ivermectin administered orally to dogs. Veterinary research communications 16, 125-130 (1992).
20. Perez R. et al. Pharmacokinetics of doramectin and ivermectin after oral administration in horses. Veterinary journal 163, 161-167 (2002).
21. Geyer J., Gavrilova O. & Petzinger E. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein-and bcrp-deficient knockout mice. Journal of veterinary pharmacology and therapeutics 32, 87-96 (2009).
22. Kiki-Mvouaka S. et al. Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug metabolism and disposition: the biological fate of chemicals 38, 573-580 (2010).
23. Cotreau M.M. et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. Journal of clinical pharmacology 43, 1108-1115 (2003).
24. Lifschitz A. et al. Moxidectin in cattle: correlation between plasma and target tissues disposition. Journal of veterinary pharmacology and therapeutics 22, 266-273 (1999).
25. Xu Q. et al. An LC-MS method for determination of milbemycin oxime in dog plasma. Journal of chromatographic science 52, 999-1004 (2014).
26. Holmstrom S.D., Totten M.L., Newhall K.B., Qiao M. & Riggs K.L. Pharmacokinetics of spinosad and milbemycin oxime administered in combination and separately per os to dogs. Journal of veterinary pharmacology and therapeutics 35, 351-364 (2012).
27. Sarasola P. et al. Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and dogs. Journal of veterinary pharmacology and therapeutics 25, 265-272 (2002).
28. Novotny M.J. et al. Safety of selamectin in dogs. Veterinary parasitology 91, 377-391 (2000).
29. Shoop W.L., Mrozik H. & Fisher M.H. Structure and activity of avermectins and milbemycins in animal health. Veterinary parasitology 59, 139-156 (1995).
30. de Jaham C. & Henry C.J. Treatment of canine sarcoptic mange using milbemycin oxime. The Canadian veterinary journal. La revue veterinaire canadienne 36, 42-43 (1995).
31. Bishop B.F. et al. Selamectin: a novel broad-spectrum endectocide for dogs and cats. Veterinary parasitology 91, 163-176 (2000).